PER-114-10已完成未知
A PHASE II PROSPECTIVE TRIAL CORRELATING THE PROGRESSION FREE SURVIVAL CYP2D6 WITH ACTIVITY IN PATIENTS WITH METASTATIC BREAST CANCER TREATED WITH SINGLE AGENT TAMOXIFE
EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG), GRUPO DE ESTUDIOS CLINICOS ONCOLOGICO DEL PERU GECOPERU,0 个研究点目标入组 37 人开始时间: 2011年4月25日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 37
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 0（—）
- 性别
- Female
入选标准
- •You must have breast adenocarcinoma with positive estrogen and / or progesterone receptors histologically confirmed.
- •Patients must have measurable or non-measurable stage III / locally advanced or metastatic breast carcinoma where surgery is not possible, as defined in Section 6.1.1. Injuries must be evaluated within 4 weeks prior to registration.
- •Age> 18 years.
- •Fertile women and sexually active men should be strongly advised to use an accepted and effective method of non-hormonal contraception. The acceptable contraceptive method includes barrier methods (eg, condoms or diaphragm) or intra uterine devices or IUDs (these may include low doses of hormones at the discretion of the Study Directorate).
- •ECOG functional status assessment of 0-2.
- •Patients with a history of central nervous system metastases are allowed since they have been treated (surgery, radiation or radiosurgery) at least 4 weeks prior to starting the study drug and do not require medication (s) to control the symptoms. Patients with leptomeningeal disease are not eligible.
- •Patients may receive concurrent radiotherapy at sites with bone disease pain or areas of impending fracture as long as radiation therapy is initiated prior to study entry and sites of measurable and non-measurable disease outside of port radiotherapy are available for follow-up. . Patients who have received previous radiation therapy must have recovered from the toxicity of previous radiation therapy.
排除标准
- •Women should not be pregnant or breastfeeding due to the harmful effects of Tamoxifen.
- •The patient should not have received chemotherapy or Trastuzumab (Herceptin) for metastatic disease. Chemotherapy or Trastuzumab or Bevacizumab in adjuvant therapy is allowed but must have been completed at least 6 weeks before starting the study. Research agents prior to metastatic treatment are not allowed. Previous investigating agents in adjuvant treatment should be discussed with the Principal Investigator of the study.
- •Prior Tamoxifen or other agents that modulate or decrease the regulation of estrogen receptors (eg Raloxifene, Fulvestrant) are not allowed. Previous aromatase inhibitor (up to 2 agents) (eg Anastrozole, Letrozole, Exemestane, Aminoglutetamide) is allowed in adjuvant or metastatic management.
- •Concurrent hormone therapy that is not part of the protocol is not allowed.
- •Concurrent chemotherapy is not allowed.
- •Patients should not take the following medications that are strong to moderate CYP2D6 inhibitors and may alter the metabolism of Tamoxifen: Paroxetine (Paxil), Fluoxetine (Prozac), Buproprion (Wellbutrin) and quindine (Cardioquin) within 2 weeks from the register.
- •Patients must not have suffered from medical or psychiatric conditions that may interfere with the conformity of the protocol, the ability to give informed consent, or the evaluation of the response or anticipated toxicities.
- •Patients should be free of disease from previous invasive malignancies for> 5 years with the exception of basal cell skin carcinoma or squamous cell treated with curative intent or carcinoma in situ of the cervix.
研究者
相似试验
尚未招募
不适用
Onderzoek naar de uitkomst van chemotherapie gevolgd door een lymfeklieroperatie en een gecombineerde behandeling van chemotherapie met uitwendige bestraling voor hoog-risico spier-ingroeiend blaaskanker (CHEMORAD-TRIAL)Bladder cancer, locally advanced disease, node positive disease, chemotherapy, lymph node dissection, chemoradiationNL-OMON27865The Netherlands Cancer Institute-Antoni van Leeuwenhoek HospitalPostbus 90203, 1006 BE, AmsterdamThe Netherlands50
已完成
2 期
PROSPECTIVE FASE-II TRIAL EVALUATING THE OUTCOME OF INDUCTION CHEMOTHERAPY FOLLOWED BY EXTENDED LYMPH NODE DISSECTION AND CHEMORADIATION FOR HIGH RISK INVASIVE BLADDER CANCER<br>'bladder cancer' and 'high-risk muscle invasive bladder cancer'100383641000499410038365NL-OMON43780Antoni van Leeuwenhoek Ziekenhuis50
进行中（未招募）
1 期
Clinical Study Evaluating the immune responses and safety of single versus two dose COVID-19 mRNA Vaccination in children (CoVacc)Healthy volunteers (paediatric subjects) with prior SARS-CoV-2 infectionMedDRA version: 23.1Level: LLTClassification code 10084464Term: COVID-19 immunizationSystem Organ Class: 100000004865EUCTR2021-005043-71-DEniversity Medical Center Utrecht200
进行中（未招募）
1 期
Clinical Study Evaluating the immune responses and safety of single versus two dose COVID-19 mRNA Vaccination in children (CoVacc)Healthy volunteers (paediatric subjects) with prior SARS-CoV-2 infectionMedDRA version: 23.1Level: LLTClassification code 10084464Term: COVID-19 immunizationSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2021-005043-71-NOniversity Medical Center Utrecht200
进行中（未招募）
1 期
Immunogenicity and reactogenicity of reduced COVID-19 vaccination regimen in children (CoVacc).Healthy volunteers (paediatric subjects) with prior SARS-CoV-2 infectionMedDRA version: 23.1Level: LLTClassification code 10084464Term: COVID-19 immunizationSystem Organ Class: 100000004865EUCTR2021-005043-71-GRniversity Medical Center Utrecht200